Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
Status:
Unknown status
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label study to evaluate the efficacy and safety in reducing
antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
Approximate 60 patients will be recruited to achieve at least 40 evaluable patients.